Skip to main content

Table 2 Internal validity of included studies

From: Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

Study

Prospective design

Multicenter enrollment

Selection bias

Performance bias

Attrition bias

Detection bias

Multivariate adjustment for potential confounders

Norikazu Masuda 2017 [7]

B

C

B

C

none reported

David Miles 2017 [8]

A

A

B

A

probably adequate

Christoph Rochlitz 2016 [20]

B

B

B

C

none reported

Christoph Zielinski 2016 [13]

A

A

B

A

probably adequate

A. Welt 2016 [17]

A

A

A

A

probably adequate

O. Trédan 2016 [21]

B

C

B

C

none reported

Denise A. Yardley 2015 [18]

B

C

A

C

none reported

Veronique Dieras 2015 [19]

B

C

A

C

none reported

Hans-Joachim Luck 2015 [16]

A

A

A

B

probably adequate

S.W. Lam 2014 [14]

A

A

A

B

probably adequate

Joseph Gligorov 2014 [15]

A

A

B

B

probably adequate

Istvan Lang 2013 [12]

A

A

B

A

probably adequate

Adam M. Brufsky 2011 [22]

A

B

A

A

probably adequate

Miguel Martin 2011 [23]

A

B

A

B

probably adequate

David W. Miles 2010 [9]

A

A

A

A

probably adequate

Robert Gray 2009 [10]

A

A

A

A

probably adequate

  1.  = yes,  = no. Risk of bias is expressed as A = low, B = moderate, C = high, or D = incomplete reporting